Recursion announces preliminary results from Phase 1b/2 TUPELO trial

Recursion announced preliminary safety and efficacy results from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational, allosteric MEK1/2 inhibitor in development for Familial Adenomatous Polyposis. These data were presented in a late-breaking oral presentation at Digestive Disease Week, DDW, 2025 in San Diego, California. As of the March 17, 2025 data cutoff in the open-label Phase 2 portion of the TUPELO trial, treatment with REC-4881 led to a preliminary median 43% reduction to date in polyp burden at the Week 13 assessment among six efficacy-evaluable patients. Other investigational agents in separate studies have reported 20-30% polyp burden reduction in 6 months1. Five of the six patients experienced reductions in polyp burden ranging from 31% to 82%, while one patient showed a substantial increase of 595% from baseline. Additionally, three of six patients achieved a greater than or equal to1-point reduction in Spigelman stage; one patient had no change, one progressed from Stage II to IV, and one had no baseline stage but was classified as Stage II at Week 13.